OCS vs OLMA: fair value comparison
Oculis Holding AG and Olema Pharmaceuticals, Inc. · Updated 2026-10-19
OCS reports in CHF, so no same-currency fair-value verdict is published for it. OLMA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, OCS currently ranks higher by quality score.
| OCS | OLMA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $8.76 | $6.58 |
| 12-month range | $7.17–$32.65 | $6.58–$35.83 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #257 of 301 Healthcare | #259 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: OCS fair value analysis · OLMA fair value analysis